Mirae Asset Global ETFs Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Sell	13,542 -1,296	-9%	-$192K	﹤0.01%	1198
2026 Q1	$1.85M	Buy	14,838 +304	+2%	+$40.3K	﹤0.01%	1202
2025 Q4	$1.94M	Buy	14,534 +1,806	+14%	+$262K	﹤0.01%	1161
2025 Q3	$1.79M	Sell	12,728 -407	-3%	-$55.1K	﹤0.01%	1190
2025 Q2	$1.65M	Sell	13,135 -1,648	-11%	-$189K	﹤0.01%	1185
2025 Q1	$1.65M	Buy	14,783 +5,577	+61%	+$707K	﹤0.01%	1240
2024 Q4	$1.26M	Sell	9,206 -2,726	-23%	-$337K	﹤0.01%	1424
2024 Q3	$1.37M	Buy	11,932 +960	+9%	+$132K	﹤0.01%	1359
2024 Q2	$1.5M	Buy	+10,972	New	+$1.5M	﹤0.01%	1222

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's NBIX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Neurocrine Biosciences (NBIX) stake by 8.7% in Q2 2026, selling an estimated $192K and leaving 13,542 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Mirae Asset Global ETFs Holdings first reported a position in NBIX in Q2 2024 and has held it in 9 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 13,542 shares of Neurocrine Biosciences worth $2.17M as of Q2 2026.
Mirae Asset Global ETFs Holdings sold 1,296 Neurocrine Biosciences shares in Q2 2026, an estimated $192K.
Neurocrine Biosciences made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1198 holding.
Mirae Asset Global ETFs Holdings first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 9 quarters since.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.